List of Belsomra drug patents

Belsomra is owned by Merck Sharp Dohme.

Belsomra contains Suvorexant.

Belsomra has a total of 2 drug patents out of which 0 drug patents have expired.

Belsomra was authorised for market use on 13 August, 2014.

Belsomra is available in tablet;oral dosage forms.

Belsomra can be used as treatment of insomnia.

The generics of Belsomra are possible to be released after 29 May, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7951797 MERCK SHARP DOHME Substituted diazepan orexin receptor antagonists
Nov, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098892 MERCK SHARP DOHME Solid dosage formulations of an orexin receptor antagonist
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
M Jan 29, 2023

Drugs and Companies using SUVOREXANT ingredient

Market Authorisation Date: 13 August, 2014

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in